MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1093/oncolo/oyaf173

Медицинская библиотека · The oncologist · 2025

Retrospective multicenter analysis of real-life toxicity and outcome of ipilimumab and nivolumab in metastatic uveal melanoma.

Ciernik Amélie, Ciernik Laure, Bonczkowitz Peter, Morak Monika, Heinzerling Lucie, Bennaceur Yacine, Lawless Aleigha, Sullivan Ryan, Kött Julian, Gebhardt Christoffer, Carter Thomas J, Nathan Paul, Tschopp Sophie, Dummer Reinhard, Ramelyte Egle

СтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

BACKGROUND

Uveal melanoma (UM) is the most common primary ocular malignancy with a high rate of metastases. While immune checkpoint inhibitors (ICIs), including ipilimumab and nivolumab (ipi + nivo), have shown efficacy in metastatic cutaneous melanoma, their success in metastatic UM (MUM) remains limited. This study evaluates toxicity and outcomes of ipi + nivo in the largest, multicenter MUM cohort.

METHODS

We analyzed 131 MUM patients treated with ipi + nivo from 2016 to 2024 across 5 international centers. Rates of toxicity, response, and survival outcomes were assessed.

RESULTS

Among 131 patients, 37.4% of patients received 4 cycles of ipi + nivo. The most common reason for ipi + nivo discontinuation (31.3%) was toxicity. Of all treated patients, 80.2% experienced immune-related adverse events (irAEs). The overall response rate (ORR) was 16.4%, and the disease control rate (DCR) was 43.4%. Progression-free survival (PFS) was three months, and the median overall survival (OS) was 18 months. Patients receiving ipi + nivo as second-line therapy had lower ORR compared to patients who received ipi + nivo as first-line therapy (P = .04). Patients with exclusively extrahepatic metastases had a better ORR and OS compared to those with hepatic or mixed metastases (P = .02, P = .02, respectively). 20.6% of patients developed eosinophilia during treatment, which was associated with improved median OS (24 months vs 15 months, P = .02).

CONCLUSIONS

Ipi + nivo shows moderate efficacy and clinically relevant toxicities in patients with MUM. Eosinophilia is a potential prognostic biomarker, that merits further investigation.

Для цитирования: Ciernik Amélie, Ciernik Laure, Bonczkowitz Peter, Morak Monika, Heinzerling Lucie, Bennaceur Yacine, Lawless Aleigha, Sullivan Ryan, Kött Julian, Gebhardt Christoffer, Carter Thomas J, Nathan Paul, Tschopp Sophie, Dummer Reinhard, Ramelyte Egle. Retrospective multicenter analysis of real-life toxicity and outcome of ipilimumab and nivolumab in metastatic uveal melanoma.. The oncologist. 2025. DOI: 10.1093/oncolo/oyaf173.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.